– A-005 is a potential first-in-class, CNS penetrant TYK2 inhibitor for the treatment of neuroinflammatory and neurodegenerative diseases – –...
Antibody rise observed in lactating mothers and in their breast milk Long-term goal is to provide protection to infants through...
MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on...
SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule...
TAMPA, Fla., April 30, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its first...
FreeClimb 54 reperfusion system Route 92 Medical's new FreeClimb 54 reperfusion system, part of a growing portfolio of neurovascular devices...
Independent Safety Committee approves increase of RECCE® 327 (R327) dose to 4,000mg intravenously (IV) over 30 minutes for six subjects,...
ROCKAWAY, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness...
Brings extensive experience in all phases of oncology drug development HANOVER, Md., April 30, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals,...
Statistically Significant Improvements with DCCR Compared to Natural History of PWS from the PATH for PWS Study in Hyperphagia and PWS-related...
AMERICAN FORK, Utah, April 30, 2024 (GLOBE NEWSWIRE) -- OrthoSelect, a leading orthodontics software company and digital orthodontics laboratory, announces...
Launching our most comprehensive test and expanding into new global marketsMELBOURNE, Australia, April 30, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies...
HUMMELSTOWN, Pa., April 30, 2024 (GLOBE NEWSWIRE) -- SIRPant Immunotherapeutics, Inc., a clinical-stage immuno-oncology company focusing on developing next-generation macrophage-based...
BOSTON, April 30, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company driven to improve the lives of...
Preliminary results from the Company’s ongoing Phase 2/3 study expected in the first half of 2025WOODCLIFF LAKE, N.J., April 30,...
ORANGE, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), today announced that John Kao, founder and...
SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational...
– Part 2 of REFRαME-O1, the registration-directed study of luvelta for patients with platinum-resistant ovarian cancer (PROC), is open for...
MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics...
OREM, Utah, April 30, 2024 (GLOBE NEWSWIRE) -- Reflect Scientific, Inc. (Symbol: RSCF), a leading provider of advanced freezing solutions...